On Monday, the New Jersey pharma announced its rVSV-ZEBOV has won the FDA’s Breakthrough Therapy Designation and the EMA’s Priority Medicines status.

What’s a quick way to nab market share from a competitor? Roll out a superior product at the same price--and that’s what Shire’s confident it’s doing with dry…

Boehringer was hoping to get some more mileage out of targeted lung cancer med Gilotrif. But those hopes have been dashed by a data monitoring committee.

Worried that GlaxoSmithKline or AstraZeneca might pull up their U.K. roots in the wake of Brexit? Rest easy. Both companies are set to reassure the world this…

Roche won another reprieve in its fight againstthousands of Accutane safety claims. The drugmaker persuaded a New Jersey appeals court to overturn an $18M jury…

With the vast majority of drugs and drug ingredients being manufactured outside the U.S., the FDA has had to step up its international oversight and often ban…

Bristol-Myers Squibb’s immunotherapy Opdivo has been powering ahead, racking up sales and new FDA approvals one after another. And with cancer-fighting…

The sun is finally shining on drug company payments to doctors in Europe, and payment information has begun to trickle out.

Valeant just got a new weapon in its battle with AstraZeneca for the opioid-induced constipation throne. But don't expect oral Relistor to power that…